Strategic Partnership with Wistar Institute

The Fox Chase Chemical Diversity Center Announces that is Has Established a Strategic Partnership With the Prestigious Wistar Institute Doylestown, PA. May 11, 2015- The prestigious Wistar Institute (www.wistar.org) is the oldest independent nonprofit biomedical...

Phase I SBIR Grant

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease” Doylestown, PA. March 26, 2015- FCCDC is pleased to announce that it has been awarded...

Phase I SBIR Grant

The Fox Chase Chemical Diversity Center is Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Development of Drugs that Target the M2 Proton Channel from Influenza Virus” Doylestown, PA. February 2, 2015- FCCDC is pleased to announce that it has been...

Phase I STTR

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Development of Small Molecule Therapeutics Against RNA Viruses” Doylestown, PA. January 23, 2015- FCCDC is pleased to announce that it has been awarded a Phase I STTR...

$100,000 Keystone Innovation Zone Tax Credit

The Fox Chase Chemical Diversity Center Announces it Has Received a $100,000 Keystone Innovation Zone Tax Credit from the Department of Community & Economic Development of the Commonwealth of Pennsylvania Doylestown, PA. December 29, 2014- FCCDC is pleased to...

Direct to Phase II SBIR

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct to Phase II SBIR Entitled “Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses” Doylestown, PA. December 24, 2014- FCCDC is pleased to announce that it was...